Christophe Demaison is the founder of Ena Respiratory. Ena Respiratory has raised $33M in total funding. Latest round: Series B.
Christophe Demaison is the Managing Director and CEO of ENA Respiratory, a clinical-stage pharmaceutical company headquartered in Melbourne, Australia developing antiviral host defense enhancers for respiratory infections. He leads the company's development of INNA-051, a nasal spray designed to protect against symptomatic viral respiratory infections including COVID-19, flu, and RSV. Demaison has overseen the company's progression through multiple funding rounds, including a Series B financing in October 2025.
Full founder directory · Investor directory · Company funding database · Fundraising library